'You are the...': Internet convinced Shivon Zilis is the right woman for Elon as she posts this on Musk's 54th birthday
Shivon Zilis posted a childhood photo of Elon Musk wishing him on his 54th birthday.
Social media is convinced that Neuralink director Shivon Zilis is the right partner for
Elon Musk
as Shivon posted a throwback collage on Tesla CEO's 54th birthday -- showcasing a little Elon Musk being happy seeing his birthday cake juxtaposed with a present-day Elon Musk excited seeing his 54th birthday cake.
"Happy birthday rocket man," Shivon posted.
Shivon Zilis and Elon Musk have four children together: twins Strider and Azure (born in November 2021), a daughter named Arcadia, and a son named Seldon Lycurgus.
Social media users commented on the 'thoughtful and heartfelt' gesture of Shivon that she took the effort to recreate a childhood memory for Elon. "You are the right woman for Elon," one wrote. "I hope Elon appreciates you Shivon," another wrote.
— shivon (@shivon)
Indian-origin Shivon Zilis is Elon Musk's current partner who met Musk at OpenAI. She has been featured in Forbes 30 Under 30, LinkedIn 35 Under 35, and multiple 'Top Women in AI' lists.
Elon Musk arranged a milestone birthday present for himself as a Tesla drove itself from its Texas factory to a customer in Austin in a historic milestone for Tesla. 'The first fully autonomous delivery of a Tesla Model Y from factory to a customer home across town, including highways, was just completed a day ahead of schedule,' Musk posted on Friday.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Perdagangkan CFD Emas dengan Broker Tepercaya
IC Markets
Mendaftar
Undo
'There were no people in the car at all and no remote operators in control at any point.
FULLY autonomous.'
Elon Musk had a tumultuous year both in his personal and professional life -- with drug scandals, baby mama controversies and his major fallout with President Donald Trump, and to top it all, his companies suffered owing to his political involvement.
On Elon Musk's birthday, the Senate cleared the 'Big, Beautiful Bill' which was the main flashpoint between Elon Musk and the Donald Trump administration. Musk once again condemned the bill, called it "utterly insane and destructive" and predicted that it will destroy million of jobs in America.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Torrent Pharma to acquire controlling stake in JB Chemicals from KKR
Ahmedabad-based drugmaker Torrent Pharmaceuticals is set to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR, at an equity valuation of ₹25,689 crore. The deal will be followed by a merger of the two entities, the company announced on Sunday evening. The deal will strengthen Torrent's presence in the Indian market, as well as facilitate its entry into the fast-growing contract development and manufacturing (CDMO) segment. Torrent will acquire a 46.39% equity stake (on a fully diluted basis) in JB Pharma through a share purchase agreement for ₹11,917 crore at ₹1,600 per share, followed by a mandatory open offer to acquire up to 26% of the company's shares from public shareholders, at an open offer price of ₹1,639.18 per share. Torrent also intends to acquire up to 2.80% of equity shares from certain employees of JB Pharma at the same share price as KKR, the company said in a release. The investment in JB Pharma yielded an over 5x return for KKR with a gross internal rate of return of about 36%, a person aware of the development, who did not wish to be quoted, told Mint. KKR has had a strong track record of healthcare investments in India, including a $600 million financing to Manipal Group recently and a 5x return on its investment in Max Healthcare in 2022. The acquisition will be followed by a merger between Torrent and JB Pharma through a scheme of arrangement. JB Pharma's shares rose 2.3% to ₹1,792.20 apiece, while those of Torrent Pharma settled 4.7% higher at ₹3,375 on the NSE on Friday. The acquisition will provide Torrent access to a fast-growing India franchise, with JB's leading brands in the chronic segment, and entry into untapped therapeutic areas like ophthalmology, strengthen Torrent's market share in the Indian market, and facilitate its entry into the CDMO segment. It will also aid consolidation in key international markets, the company said. 'Torrent's deep India presence and JB Pharma's fast growing India business, combined with the CDMO and international footprint, offers immense potential to scale both revenue and profitability," Samir Mehta, executive chairman, Torrent Pharmaceuticals, said in the statement. 'Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent," he added. Torrent Pharma was engaged in prolonged talks to acquire KKR's stake in JB Pharma last year. The deal, however, fell through over valuation concerns. KKR acquired a 54% stake in JB Pharma from the promoters, the Mody family, in July 2020 for about ₹3,100 crore, or ₹745 per share. The investment firm sold over 5% of stake in the company in March 2025 through block deals for ₹1,459 crore, bringing its holding down to 47.84%. Torrent Pharmaceuticals has grown over the years through inorganic moves. In 2017, it acquired women's healthcare brands from Novartis, as well as Unichem's Indian branded business along with its Sikkim plant. In 2022, it acquired Curatio Healthcare for ₹2,000 crore. In an interview with the Economic Times earlier this month, Torrent's managing director-designate Aman Mehta said the company is aiming to be one of the top three pharma companies in the Indian market in the next three to five years. JB Pharma is one of the fastest growing pharma companies in India, and comes with flagship brands such as Cilacar, Metrogyl, Nicardia and Rantac. The company also exports its finished formulations to over 40 countries, including the US, and is a leading CDMO player in the segment of medicated lozenges. JB Pharma recorded revenue of ₹3,918 crore in FY24-25, growing 12% year-on-year. Of this, its revenue from the domestic market was ₹2,269 crore, growing 20% YoY. 'Over the past five years, JB Pharma has emerged as one of India's fastest growing pharmaceutical players, owing to KKR's strategic guidance, stewardship of our independent directors and a focused strategic and executional excellence by the management team. We have built a strong foundation to deliver market-leading growth as well as consistent improvement in profitability in the medium and long term," said Nikhil Chopra, chief executive officer and whole time director of JB Pharma.
Hindustan Times
an hour ago
- Hindustan Times
Prada's Kolhapuri story reveals hidden opportunities
Jun 29, 2025 10:17 PM IST In a globalised, hyperconnected world, how do we protect local art, craft, cultural markers, and related intellectual property from appropriation by foreign commercial interests — via 'inspiration' — without any of the gains flowing to the artisans and craftsmen? This is the question at the centre of the latest instance of distinctly Indian artisanry being appropriated by a multi-billion Western fashion-house. Prada recently featured footwear that was virtually indistinguishable from Kolhapuri chappals. What was passed off as the fashion label's creative output, has been the signature product of craftsmen of the Kolhapur region for centuries now, acquiring its GI tag in 2019. What was passed off as the fashion label's creative output, has been the signature product of craftsmen of the Kolhapur region for centuries now (Hindustan Times) Indian art, artisanry, and crafts have had many imprints across Western fashion. On the one hand, there is lifting without attributing — Gucci's kurta copy, Toteme's 'Scandinavian scarf' that was clearly a dupatta — and on the other is acknowledgment and collaboration, as Dior did with its 2022 fashion show, where it showcased the work of Indian artisans including embroiderers. Cultural appropriation dilutes the uniqueness and identity of the root product/design and must be treated as a grave ethical violation in an industry centred on original creative output and IP. But, the latest episode also highlights an opportunity for Indian artisans. Pressured into acknowledging its sandal's Indian roots, Prada has reportedly expressed keenness to work with local artisans. Much of Indian artisanry shares the same story, of artisans' penury given the lack of scale and limited markets. Against such a backdrop, a Prada or a Dior represent access to a wider market, and with premium valuation for products and designs. So, even as the artisans and other stakeholders push for acknowledgment, the larger fight has to be about ensuring participation. Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away! -Login Now!
Economic Times
an hour ago
- Economic Times
J&K Bank appoints Ketan Kumar Joshi as new CFO
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The Jammu and Kashmir Bank on Sunday announced the appointment of Ketan Kumar Joshi as its new chief financial officer for a term of three has replaced Fayaz Ahmad Ganai, a spokesperson of the J&K Bank said. The Bank notified the appointment to the stock exchanges in accordance with SEBI Regulations."A seasoned professional in banking and finance, Joshi brings over two decades of extensive experience across Indian and international financial institutions," the spokesperson joining the J&K Bank, Joshi served as CFO at North East Small Finance Bank Ltd. (2019-2024), where he successfully led a number of critical also spearheaded the bank's system migration from FIS (PROFILE) to BSG (TURING), ensuring capital growth aligned with business expansion and regulatory has served in Afghanistan with Maiwand Bank Bakhtar Bank , and Ghazanfar Bank. He also served as senior vice president at Bank of Tokyo-Mitsubishi UFJ Ltd, Mumbai.
